Skip to content

Nitrofurantoin Macrocrystals 3 Days Versus 7 Days in the Treatment of Women With Uncomplicated Cystitis

Nitrofurantoin Macrocrystals 3 Days Vs. 7 Days in the Treatment of Women With Uncomplicated Cystitis

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00361998
Enrollment
400
Registered
2006-08-09
Start date
2006-09-30
Completion date
2007-01-31
Last updated
2007-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystitis

Keywords

Uncomplicated Cystitis, Nitrofurantoin Macrocrystals

Brief summary

Our guidelines in the community recommend the use of NM for the treatment of women with community acquired UTI. While the length of treatment for uncomplicated cystitis with quinolones or TMP-SMX is three days, NM is recommended for seven days. However, there are not sufficient papers that establish the optimal length of treatment with NM in this population. The aim of this proposal is to evaluate and compare NM 3 day vs. 7 day treatment for the treatment of women with uncomplicated UTI.

Detailed description

The aim of this proposal is to evaluate and compare NM 3 day vs. 7 day treatment for the treatment of women with uncomplicated UTI. Our design is to enroll 400 women with uncomplicated cystitis and divided according to a double-blind randomization in two groups (3 days vs. 7 days). The women will be followed 7 days and 28 days clinically and bacteriologically.

Interventions

DRUGNITROFURANTOIN MACROCRYSTALS

Sponsors

Clalit Health Services
CollaboratorOTHER
HaEmek Medical Center, Israel
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

1. Premenopausal healthy women 2. Uncomplicated cystitis

Exclusion criteria

1. Postmenopausal women 2. Complicated UTI 3. Women with catheter 4. Women with recurrent UTI 5. Pregnancy 6. Diabetes Mellitus

Design outcomes

Primary

MeasureTime frame
Microbiological efficacy

Secondary

MeasureTime frame
Clinical efficacy and side effects

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026